NCT01702493View on ClinicalTrials.gov

A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

October 30, 2012

Primary Completion Date

December 5, 2012

Study Completion Date

December 5, 2012

Conditions
Psoriasis
Interventions
DRUG

Cap SRT2104

Micronized free base in a 250 mg SRT2104 (active equivalents) capsule

DRUG

Tab SRT2104 slow release

New 250 mg SRT2104 mesylate salt slow release tablet

DRUG

Tab SRT2104 intermediate release

New 250 mg SRT2104 mesylate salt intermediate release tablet

DRUG

Tab SRT2104 fast release

New 250 mg SRT2104 mesylate salt fast release tablet

DRUG

Selected formulations of SRT2104 from Part 1

SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days

DRUG

Selected formulations of SRT2104 from Part 1 single alternative dose

SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1

Trial Locations (1)

21225

GSK Investigational Site, Baltimore

All Listed Sponsors
lead

Sirtris, a GSK Company

INDUSTRY

NCT01702493 - A Study to Assess the Relative Bioavailability of New Oral Formulations of SRT2104 in Healthy Male Volunteers | Biotech Hunter | Biotech Hunter